EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival Outcomes in DCD vs DBD Heart Transplants in Patients Bridged With Fully Magnetically Levitated Centrifugal Flow Left Ventricular Assist Devices

Zachary W. Sollie, Chakradhari Inampudi, Lefan Xuan, Jingwen Zhang, Brett A. Welch, Arman Kilic

Journal of Cardiac Surgery · 2026-01 · 2026 (1)

DOI: 10.1155/jocs/7212761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiac Surgery, online erschienen am 16.07.2026. Verfasst von Zachary W. Sollie und 5 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Heart transplant (HT) for donors after circulatory death (DCD) versus donor after brain death (DBD) have not been fully explored in patients bridged with HeartMate 3 (HM3) left ventricular assist devices (Abbott, Chicago, IL). This study aims to assess survival outcomes in DCD vs DBD HT in patients bridged with HM3. Materials and Methods All adults ≥ 18 years bridged to HT with HM3 between October 18, 2018, and March 31, 2025, were identified from the UNOS database and stratified by donor type (DCD vs DBD). Primary outcome was 90‐day, 1‐year, and 3‐year survival. Multivariable risk adjustment was performed.

Results

Following exclusion, 2380 patients (296 DCD and 2084 DBD) were identified. DCD patients had longer duration of HM3 support (671 days [343.5, 1122] vs 535 days [294.5, 912.5], p 0.0005), had fewer days on waitlist (83.5 days [20, 356] vs 137.5 days [32, 426], p 0.0072), were more frequently male (82.8% vs 77.4%, p 0.0351), blood type O (55.7% vs 38.4%, p < 0.001), and status 4 listing (44.3% vs 35.2%, p < 0.001). There was no difference in survival between DCD and DBD patients at 90 days (92.9% vs 92.8%, p 0.98), 1 year (89.4% vs 88.4%, p 0.68), or 3 years (78.7% vs 82.2%, p 0.66). Following multivariable adjustment, DCD donor status was not associated with increased mortality (HR 0.97 [0.65–1.45]; p = 0.875).

Conclusion

Survival between DCD and DBD HT in patients bridged with HM3 shows no significant difference. DCD utilization has potential to safely expand the donor pool in this population.

Zitieren

APA

Sollie, Z. W., Inampudi, C., Xuan, L., Zhang, J., Welch, B. A., & Kilic, A. (2026). Survival Outcomes in DCD vs DBD Heart Transplants in Patients Bridged With Fully Magnetically Levitated Centrifugal Flow Left Ventricular Assist Devices. Journal of Cardiac Surgery, 2026(1). https://doi.org/10.1155/jocs/7212761

Vancouver

Sollie ZW, Inampudi C, Xuan L, Zhang J, Welch BA, Kilic A. Survival Outcomes in DCD vs DBD Heart Transplants in Patients Bridged With Fully Magnetically Levitated Centrifugal Flow Left Ventricular Assist Devices. Journal of Cardiac Surgery. 2026;2026(1). doi:10.1155/jocs/7212761

BibTeX
@article{Sollie2026,
  author = {Sollie, Zachary W. and Inampudi, Chakradhari and Xuan, Lefan and Zhang, Jingwen and Welch, Brett A. and Kilic, Arman},
  title = {Survival Outcomes in DCD vs DBD Heart Transplants in Patients Bridged With Fully Magnetically Levitated Centrifugal Flow Left Ventricular Assist Devices},
  journal = {Journal of Cardiac Surgery},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jocs/7212761}
}
Kostenlos starten →